JPMorgan hikes Relx price target
JPMorgan Cazenove lifted its price target on on Friday to 4,550p from 4,200p to reflect an acceleration in the Legal and STM (scientific, technical & medical) divisions driven by generative AI.
JPM noted that Relx hosted a legal seminar last week.
It said Legal growth has accelerated from 2% in 2019 to 6% last year driven by less print and more data driven analytics supported by extractive AI.
"This year growth has accelerated to 7% supported by the initial benefit of Lexis+ AI which applies generative AI to its authoritative content to drive significant productivity benefits for lawyers," JPM said.
"In January it will launch Protégé, a next-generation personalised AI assistant which tailors support to individual lawyers and law firms by applying generative AI to the user's own proprietary documents to provide more informed, accurate and contextually relevant results.
"Lexis believes it currently has the best AI product in terms of capability, speed and accuracy. We believe Protégé's personalisation further extends its lead."
JPM maintained its 'overweight' rating on the shares, which are also on its 'Analyst Focus List'.
It said the new price target would imply a 2025 price-to-earnings multiple of 35x (versus circa 28x today), which is a slight premium to the broader US peer group trading on 34x, which includes more cyclical credit bureaus and rating agencies. However, it's a discount to Relx's closest US peers of Thomson Reuters (circa 41x) and Verisk (39x) despite Relx offering similar growth.
"We believe that the sale of exhibitions on a 3-5 year view could unlock a further re-rating," JPM said.
Relx is a provider of information-based analytics and decision tools for professional and business customers.
Disclaimer & Declaration of Interest
The information, investment views and recommendations in this article are provided for general information purposes only. Nothing in this article should be construed as a solicitation to buy or sell any financial product relating to any companies under discussion or to engage in or refrain from doing so or engaging in any other transaction. Any opinions or comments are made to the best of the knowledge and belief of the writer but no responsibility is accepted for actions based on such opinions or comments. Vox Markets may receive payment from companies mentioned for enhanced profiling or publication presence. The writer may or may not hold investments in the companies under discussion.